Bank of America Issues Pessimistic Forecast for Kura Oncology (NASDAQ:KURA) Stock Price

Kura Oncology (NASDAQ:KURA) had its target price reduced by stock analysts at Bank of America from $36.00 to $29.00 in a report released on Friday,Benzinga reports. The firm currently has a “buy” rating on the stock. Bank of America‘s price objective suggests a potential upside of 168.52% from the company’s previous close.

Several other research firms have also recently issued reports on KURA. HC Wainwright lifted their price objective on Kura Oncology from $32.00 to $37.00 and gave the stock a “buy” rating in a report on Thursday. JMP Securities reaffirmed a “market outperform” rating and issued a $32.00 price target on shares of Kura Oncology in a research note on Tuesday, November 19th. Stifel Nicolaus downgraded Kura Oncology from a “buy” rating to a “hold” rating and reduced their price objective for the company from $26.00 to $19.00 in a research note on Monday, October 14th. UBS Group began coverage on shares of Kura Oncology in a research note on Thursday, October 24th. They set a “buy” rating and a $27.00 target price on the stock. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Kura Oncology in a report on Thursday. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $29.38.

Kura Oncology Stock Up 7.4 %

Shares of NASDAQ KURA opened at $10.80 on Friday. The firm has a market cap of $839.81 million, a price-to-earnings ratio of -4.58 and a beta of 0.86. The company’s 50-day simple moving average is $17.88 and its 200-day simple moving average is $19.69. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02. Kura Oncology has a 52-week low of $9.06 and a 52-week high of $24.17.

Hedge Funds Weigh In On Kura Oncology

Several institutional investors and hedge funds have recently bought and sold shares of KURA. nVerses Capital LLC acquired a new stake in shares of Kura Oncology during the 3rd quarter worth about $25,000. SG Americas Securities LLC purchased a new position in Kura Oncology during the first quarter worth about $110,000. Point72 DIFC Ltd acquired a new stake in shares of Kura Oncology during the third quarter valued at about $146,000. Quarry LP acquired a new stake in shares of Kura Oncology during the second quarter valued at about $196,000. Finally, Erste Asset Management GmbH purchased a new stake in shares of Kura Oncology in the 3rd quarter valued at approximately $215,000.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.